{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:33Z","timestamp":1792014573643,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251962"],"award-info":[{"award-number":["BK20251962"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["2024CICCPMHR020"],"award-info":[{"award-number":["2024CICCPMHR020"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573366"],"award-info":[{"award-number":["82573366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103203","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:14:19Z","timestamp":1787411659000},"page":"103203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges"],"prefix":"10.1016","volume":"150","author":[{"given":"Zhiyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103203_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103203_bb0010","first-page":"850","article-title":"Epidemiological characteristics of lung cancer in China and worldwide","volume":"47","author":"Ding","year":"2025","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other Osimertinib resistance mechanisms and Clinical landscape of NSCLC post-Osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0020","article-title":"Safety and efficacy of Osimertinib in patients with non\u2013small-cell lung cancer and uncommon tumoral epidermal growth factor receptor mutations: a systematic review and single-arm meta-analysis","volume":"8","author":"Priantti","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103203_bb0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0035","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2024.0470","article-title":"Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer","author":"Wen","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103203_bb0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4062\/biomolther.2024.146","article-title":"Mechanism of action and pharmacokinetics of approved bispecific antibodies","volume":"32","author":"Choi","year":"2024","journal-title":"Biomol & Therapeutics"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J Biol Eng"},{"key":"10.1016\/j.ctrv.2026.103203_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104841","article-title":"In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974","volume":"66","author":"Harada","year":"2020","journal-title":"Toxicol In Vitro"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103203_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0336791","article-title":"Multispecific antibodies: bioanalytics for early-stage screening and characterization of mispairing profiles","volume":"20","author":"Melo","year":"2025","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103203_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0065","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1944017","article-title":"An integrated approach for characterizing immunogenic responses toward a bispecific antibody","volume":"13","author":"Cohen","year":"2021","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0070","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2362789","article-title":"Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG(1) antibodies","volume":"16","author":"Tsai","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.ctrv.2026.103203_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114325","article-title":"Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate","volume":"388","author":"Jing","year":"2025","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0085","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103203_bb0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0100","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers-current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103203_bb0105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103203_bb0110","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-25-1034","article-title":"FDA approval summary: Blinatumomab for the treatment of B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy","volume":"31","author":"Rabik","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0115","first-page":"58","article-title":"Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy","volume":"9","author":"Kang","year":"2026","journal-title":"Antib Ther"},{"key":"10.1016\/j.ctrv.2026.103203_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104912","article-title":"Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy","volume":"214","author":"Zhang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0125","article-title":"Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses","volume":"6","author":"Lin","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2026.103203_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679271","article-title":"Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances","volume":"16","author":"Brancewicz","year":"2025","journal-title":"Front Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2026.103203_bb0135","article-title":"1168 novel bispecific macrophage engager (BiME) antibodies activate T cells and induce durable immune memory to suppress tumor growth","volume":"13","author":"Gao","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2026.2613561","article-title":"NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells","volume":"15","author":"Heger","year":"2026","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103203_bb0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680838","article-title":"Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update","volume":"16","author":"Park","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0155","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.061","article-title":"OA11.03 efficacy and safety of Rilvegostomig, an anti-PD-1\/TIGIT bispecific, for CPI-na\u00efve metastatic NSCLC with PD-L1 1-49% or \u226550%","volume":"19","author":"Hiltermann","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0170","article-title":"Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0175","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"ATG-101 is a tetravalent PD-L1x4-1BB bispecific antibody that stimulates antitumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103203_bb0180","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2024.42.16_suppl.2520","article-title":"Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab","volume":"42","author":"Kyi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103203_bb0185","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1007\/s00259-024-06742-6","article-title":"Radiolabelling and preclinical characterisation of [(89)Zr]Zr-Df-ATG-101 bispecific to PD-L1\/4-1BB","volume":"51","author":"Cao","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103203_bb0190","article-title":"Neoadjuvant retlirafusp alfa (anti-PD-L1\/TGF-beta bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial","volume":"11","author":"Pan","year":"2026","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103203_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111722","article-title":"Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects","volume":"28","author":"Zhong","year":"2025","journal-title":"iScience"},{"issue":"10481","key":"10.1016\/j.ctrv.2026.103203_bb0200","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103203_bb0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21037\/tlcr-2025-1-1380","article-title":"The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies","volume":"15","author":"Liu","year":"2026","journal-title":"Translational Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad Clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103203_bb0215","first-page":"1179","article-title":"Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)","volume":"47","author":"Amivantamab Clinical A, Adverse reaction management consensus expert G","year":"2025","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0220","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103203_bb0225","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 fusion-positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-025-02163-3","article-title":"Zanidatamab: First Approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103203_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0240","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/17474086.2022.2131526","article-title":"Emicizumab: a novel drug in hemophilia a prophylaxis - a narrative review","volume":"15","author":"Mazurkiewicz","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0245","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","article-title":"Emicizumab: the hemophilia a game-changer","volume":"109","author":"Andrade","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0250","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung Cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0255","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103203_bb0260","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung Cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0265","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s40265-025-02207-8","article-title":"Linvoseltamab: First Approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103203_bb0270","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103203_bb0275","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s40265-024-02112-6","article-title":"Odronextamab: first approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103203_bb0280","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103203_bb0285","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1200\/JCO.2026.44.16_suppl.8089","article-title":"DAREON-8: updated efficacy and safety from a phase I dose-escalation\/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)","volume":"44","author":"Peters","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103203_bb0290","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2024.42.16_suppl.4012","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0295","first-page":"S104","volume":"36","author":"Naidoo","year":"2025","journal-title":"Ann Oncol"},{"issue":"10, Supplement 1","key":"10.1016\/j.ctrv.2026.103203_bb0300","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1016\/j.jtho.2025.09.1050","article-title":"P3.18.35 ARTEMIDE-Lung02: a phase 3 global study of Rilvegostomig or Pembrolizumab plus chemotherapy for 1L metastatic squamous NSCLC","volume":"20","author":"Lu","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103203_bb0305","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103203_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2026.103203_bb0315","article-title":"1194 mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects","volume":"11","author":"Zhong","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2024.23091","article-title":"Ivonescimab plus chemotherapy in patients with EGFR variant non-small cell lung Cancer","volume":"333","author":"Liu","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: first global approval","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103203_bb0330","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103203_bb0335","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA approval summary: Amivantamab for the treatment of patients with non-small cell lung Cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103203_bb0340","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtho.2025.05.012","article-title":"Amivantamab in participants with advanced NSCLC and MET exon 14 skipping mutations: final results from the CHRYSALIS study","volume":"20","author":"Krebs","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103203_bb0345","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2026.103203_bb0350","article-title":"Squamous non-small cell lung cancer: current and emerging treatment options","author":"Paik","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103203_bb0355","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","volume":"22","author":"Wang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103203_bb0360","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (London, England)"},{"key":"10.1016\/j.ctrv.2026.103203_bb0365","article-title":"Safety and efficacy of antiangiogenesis agents in patients with squamous cell carcinoma of the lung: time to revise outdated constraints","volume":"1","author":"Pabani","year":"2024","journal-title":"JCO Oncol Adv"},{"issue":"17_suppl","key":"10.1016\/j.ctrv.2026.103203_bb0370","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non\u2013small cell lung cancer: overall survival results of the phase 3 HARMONi-6 trial","volume":"44","author":"Zhiwei","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0375","article-title":"Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions","volume":"17","author":"Wang","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1367204","article-title":"The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation","volume":"14","author":"Man","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103203_bb0385","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"10516","key":"10.1016\/j.ctrv.2026.103203_bb0390","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0395","article-title":"OA10.04 phase II study of Iza-Bren (BL-B01D1) combo with Osimertinib in EGFR mutated locally advanced or metastatic NSCLC patients","volume":"20","author":"Zhou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1691980","article-title":"Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"issue":"10, Supplement 1","key":"10.1016\/j.ctrv.2026.103203_bb0405","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jtho.2025.09.175","article-title":"MA10.03 efficacy and safety of Cadonilimab plus Pulocimab in NSCLC patients who progressed following prior immunotherapy: a phase 1b\/2 study","volume":"20","author":"Zheng","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103203_bb0410","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/ajrccm\/aamaf124","article-title":"Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions","volume":"212","author":"Papavassiliou","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103203_bb0415","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of Tarlatamab in patients with neuroendocrine prostate Cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103203_bb0420","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"New England J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0425","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/2159-8290.CD-25-1483","article-title":"Circulating tumor cells predict response to the DLL3-targeting bispecific antibody Tarlatamab","volume":"16","author":"Mishra","year":"2026","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103203_bb0430","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103203_bb0435","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"10515","key":"10.1016\/j.ctrv.2026.103203_bb0440","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"The Lancet."},{"issue":"9","key":"10.1016\/j.ctrv.2026.103203_bb0445","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103203_bb0450","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0455","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag129","article-title":"Landscape of T-cell engagers in solid tumors","volume":"31","author":"Garcia-Lorenzo","year":"2026","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0460","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103203_bb0465","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of Tarlatamab in small cell lung Cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103203_bb0470","doi-asserted-by":"crossref","first-page":"88","DOI":"10.36401\/JIPO-25-36","article-title":"Bispecific antibodies in solid tumors: mechanistic insights, Clinical advances, and future directions","volume":"9","author":"Almosa","year":"2026","journal-title":"J Immunother Precis Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0475","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/ph16101461","article-title":"Bispecific antibodies in lung Cancer: a state-of-the-art review","volume":"16","author":"Khosla","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1664\u20133224 (Electronic)","key":"10.1016\/j.ctrv.2026.103203_bb0480","article-title":"Unlocking new horizons in oncology: ivonescimab\u2019s dual-target approach to anti-VEGF\/PD-1(L1) therapy","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103203_bb0485","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"New England J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103203_bb0490","article-title":"Dual biomarker strategies for liquid biopsy: integrating circulating tumor cells and circulating tumor DNA for enhanced tumor monitoring","volume":"15","author":"Moon","year":"2025","journal-title":"Biosensors (Basel)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:11:44Z","timestamp":1792012304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":98,"alternative-id":["S0305737226001179"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103203","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103203"}}